SCHEMBL6610147

SCHEMBL6610147

COCC(=O)Oc1cc[c]cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GAA P10253 3/20 0.45
TDP1 Q9NUW8 3/20 0.43
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
CA2 P00918 1/20 0.39
ESR1 P03372 2/20 0.38
HIF1A Q16665 2/20 0.38
RECQL P46063 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.36
NPC1 O15118 1/20 0.36
ELANE P08246 1/20 0.35
BCL9 O00512 1/20 0.33
CTNNB1 P35222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5696642 0.86 KMT2A (0.59) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL248163 0.80 GAA (0.50) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL18087017 0.80 LMNA (0.53) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL128042 0.80 KMT2A (0.58) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL27283394 0.80 LMNA (0.66) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL130836 0.77 BCL9 (0.56) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL28905911 0.77 LMNA (0.50) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL11230246 0.76 KMT2A (0.39) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL1978709 0.76 ALOX15 (0.45) KMT2ALMNAALDH1A1MAPTHTT
SCHEMBL7928066 0.76 KMT2A (0.53) KMT2ALMNAALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140895-B1 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO (JP) 2004-03-24 EP claimed
WO-2003018019-A2 NEW USE OF CYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-06 WO claimed
EP-1140895-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP claimed
WO-2000040576-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 WO claimed
EP-0655461-B1 Cyclic amino acid derivatives having ACE and NEP inhibiting activity NOVARTIS AG (CH) 2000-06-07 EP claimed
WO-1997011717-A1 TREATMENT OF CHRONIC PROGRESSIVE RENAL FAILURE NOVARTIS AG (CH) 1997-04-03 WO claimed
US-5506244-A TREATING CARDIOVASCULAR DISORDERS CIBA-GEIGY CORPORATION (US) 1996-04-09 US claimed
EP-0655461-A1 Cyclic amino acid derivatives having ACE and NEP inhibiting activity CIBA-GEIGY AG (CH) 1995-05-31 EP claimed
EP-1140895-B1 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO (JP) 2004-03-24 EP disclosed
EP-1140895-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000040576-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 WO disclosed
EP-0655461-B1 Cyclic amino acid derivatives having ACE and NEP inhibiting activity NOVARTIS AG (CH) 2000-06-07 EP disclosed
US-5668158-A TREATMENT OF CARDIOVASCULAR DISORDERS NOVARTIS CORPORATION (US) 1997-09-16 US disclosed
WO-1997011717-A1 TREATMENT OF CHRONIC PROGRESSIVE RENAL FAILURE NOVARTIS AG (CH) 1997-04-03 WO disclosed
US-5506244-A TREATING CARDIOVASCULAR DISORDERS CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
US-5432186-A Enzyme inhibitors CIBA-GEIGY CORPORATION (US) 1995-07-11 US disclosed
EP-0655461-A1 Cyclic amino acid derivatives having ACE and NEP inhibiting activity CIBA-GEIGY AG (CH) 1995-05-31 EP disclosed